登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《bioRxiv，6月6日，Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-06-09

  • Synthetic Antibodies neutralize SARS-CoV-2 infection of mammalian cells

    Shane Miersch, Mart Ustav, Zhijie Li, James B. Case, Safder Ganaie, Giulia Matusali, Francesca Colavita, Daniele Lapa, Maria R. Capobianchi, View ORCID ProfileGuiseppe Novelli, Jang B. Gupta, Suresh Jain, Pier Paolo Pandolfi, Michael S. Diamond, Gaya Amarasinghe, James M. Rini, Sachdev S. Sidhu

    doi: https://doi.org/10.1101/2020.06.05.137349

    Abstract

    Coronaviruses (CoV) are a large family of enveloped, RNA viruses that circulate in mammals and birds but have crossed the species barrier to infect humans seven times. Of these, three pathogenic strains have caused zoonotic infections in humans that result in severe respiratory syndromes including the Middle East Respiratory Syndrome (MERS-CoV), severe acute respiratory syndrome (SARS-CoV), and now SARS-CoV-2 coronaviruses, the latter of which is the cause of the ongoing pandemic of coronavirus disease 2019 (COVID-19). Here, we describe a panel of synthetic monoclonal antibodies, built on a human framework, that bind SARS-CoV-2 spike protein, compete for binding with ACE2, and potently inhibit infection by SARS-CoV-2. These antibodies were found to have a range of neutralization potencies against live virus infection in Vero E6 cells, potently inhibiting authentic SARS-CoV-2 virus at sub-nanomolar concentrations. These antibodies represent strong immunotherapeutic candidates for treatment of COVID-19.

    Competing Interest Statement

    S.S, P.P.P and S.J, are cofounders of Virna Therapeutics. The company is developing novel therapies for COVID-19 and other viruses.

  • 原文来源：https://www.biorxiv.org/content/10.1101/2020.06.05.137349v1
216浏览量
原文链接
相关报告

  • 《bioRxiv，6月10日，Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-11
    • Potent synthetic nanobodies against SARS-CoV-2 and molecular basis for neutralization View ORCID ProfileDianfan Li, View ORCID ProfileTingting Li, View ORCID ProfileHongmin Cai, View ORCID ProfileHebang Yao, View ORCID ProfileBingjie Zhou, Yapei Zhao, View ORCID ProfileWenming Qin, View ORCID ProfileCedric A.J. Hutter, Yanling Lai, Juan Bao, Jiaming Lan, Gary Wong, View ORCID ProfileMarkus Seeger, View ORCID ProfileDimitri Lavillette doi: https://doi.org/10.1101/2020.06.09.143438 Abstract SARS-CoV-2, the Covid-19 causative virus, adheres to human cells through binding of its envelope Spike protein to the receptor ACE2. The Spike receptor-binding domain (S-RBD) mediates this key event and thus is a primary target for therapeutic neutralizing antibodies to mask the ACE2-interacting interface. Here, we generated 99 synthetic nanobodies (sybodies) using ribosome and phage display. The best sybody MR3 binds the RBD with KD of 1.0 nM and neutralizes SARS-CoV-2 pseudovirus with IC50 of 0.40 μg/mL. Crystal structures of two sybody-RBD complexes reveal a common neutralizing mechanism through which the RBD-ACE2 interaction is competitively inhibited by sybodies. The structures allowed the rational design of a mutant with higher affinity and improved neutralization efficiency by ≈24-folds, lowering the IC50 from 12.32 to 0.50 μg/mL. Further, the structures explain the selectivity of sybodies between SARS-CoV strains. Our work presents an alternative approach to generate neutralizers against newly emerged viruses.
    174浏览量
    原文链接

  • 《bioRxiv，6月9日，The hypothalamus as a hub for putative SARS-CoV-2 brain infection》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-10
    • The hypothalamus as a hub for putative SARS-CoV-2 brain infection Sreekala Nampoothiri, Florent Sauve, Gaetan Ternier, Daniela Fernandois, Caio Coelho, Monica Imbernon, Eleonora Deligia, Romain Perbet, Vincent Florent, Marc Baroncini, Florence Pasquier, Francois Trottein, Claude-Alain Maurage, Virginie Mattot, Paolo Giacobini, S. Rasika, View ORCID ProfileVincent Prevot doi: https://doi.org/10.1101/2020.06.08.139329 Abstract Most patients with COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), display neurological symptoms, and respiratory failure in certain cases could be of extra-pulmonary origin. With reports detecting SARS-CoV-2 in some post-mortem patient brains, the routes, targets and consequences of brain infection merit investigation. Hypothalamic neural circuits play key roles in sex differences, diabetes, hypertension, obesity and aging, all risk factors for severe COVID-19, besides being connected to brainstem cardiorespiratory centers. Here, human brain gene-expression analyses reveal that the hypothalamus and associated regions express angiotensin-converting enzyme 2 and transmembrane proteinase, serine 2, which mediate SARS-CoV-2 cellular entry, in correlation with several genes or pathways involved in physiological functions or viral pathogenesis. Immunolabeling in human and animal brains suggests that the hypothalamus could be central to SARS-CoV-2 brain invasion through multiple routes, and that sex hormones and metabolic diseases influence brain susceptibility.
    82浏览量
    原文链接